Latest Content

Check out the pipeline updates from July!

Learn how an experienced psychiatrist structures first visits—from chief complaint to treatment plan—using empathic listening in telehealth or in person.

Retrospective cohort study of 1305 adults finds specialized virtual behavioral health care produced clinically meaningful gambling symptom improvement within 14 days.

FDA clears first triple reuptake ADHD drug Simtriyo, offering nonstimulant relief for adults and kids 6+ with executive and emotional symptoms.

Three posters presented at APA 2026 detail real-world treatment patterns, pooled long-term cardiometabolic safety, and urinary adverse event rates with xanomeline and trospium chloride.

From long-acting antipsychotics to psilocybin and new ADHD meds, clinicians weigh emerging therapies reshaping depression and postpartum care.

How can new Alzheimer therapies benefit patients today?

Emerging evidence shows eating disorders in male athletes are widely underrecognized, as screening tools built around female presentations overlook muscularity-driven behaviors like compulsive exercise, rigid dieting, and supplement misuse.

A first-in-vivo PET study finds M1 receptor availability reduced 13% to 19% across brain regions in schizophrenia, strengthening the case for muscarinic-targeted treatment.

DSM's real weakness isn't categories—it's weak science. Explore when disorders are diseases vs dimensions, and why overlap misleads.

Psychiatrists push to normalize sexual health talks, address medication-related sexual side effects, and reduce stigma with holistic care and patient-safe communication.

Brain capital drives competitiveness—see how ROI-focused mental health care and responsible AI expand access, build resilience, and boost productivity.

PMN310 shows strong 6‑month safety in early Alzheimer disease, with zero ARIA‑E and encouraging tau biomarker shifts before 2027 data.